MannKind received U.S. Food and Drug Administration approval for Furoscix ReadyFlow, an at-home autoinjector for fluid overload in heart failure or chronic kidney disease, and concurrently completed a roughly $50 million private placement. The company's shares have returned 52.96% over the past 90 days but are down 26.25% year to date, with a one-year total shareholder return of 1.72%. A widely followed narrative on the stock pegs fair value at $7.59 per share versus the last close of $4.13, implying the stock is undervalued, though that view depends on a sharp swing into profitability and faster revenue growth. MannKind's current price-to-sales ratio of 3.5 times sits above the peer average of 2.9 times but below a fair ratio estimate of 5 times, reflecting mixed valuation signals. The company continues to face execution and concentration risk tied to Afrezza uptake and a narrow product portfolio.
MannKind CorpFDA approval for Furoscix ReadyFlow